九月17号四个IPO# Stock
O*N
1 楼
【 以下文字转载自 xiaoyaogu 俱乐部 】
发信人: OKMSDN (假作真时真亦假), 信区: xiaoyaogu
标 题: 九月17号四个IPO
发信站: BBS 未名空间站 (Mon Sep 15 22:34:45 2014, 美东)
Wednesday, September 17
Home health and human services provider, Civitas Solutions (NYSE: CIVI),
serves handicapped individuals who are intellectually, behaviorally, or
physically challenged. The company focuses on providing quality programs
that are also cost effective.
As of June 30, the company had nearly 30,000 clients being served by a
workforce of 20,000. Underwriters Barclays, Merrill Lynch and UBS expect to
sell 11.7 million shares for $20 to $23 per share.
ProQR (NASDAQ: PRQR), on the other hand, is “born from the dream to beat
cystic fibrosis in one child,” according to its S-1. The company’s RNA-
based treatment is designed for use with patients suffering from cystic
fibrosis. There is also believe the treatment may address other genetic
disorders caused by single protein genetic mutation.
Underwriters Leerink Partners and Deutsche Bank expect to price 6.25 million
shares between $11 and $13 apiece.
rEVO Biologics (NASDAQ: RBIO) specializes in developing and commercializing
drugs for patients with rare, life-threatening conditions. To date, the
company has one commercial product, A Tryn, that is used to prevent blood
clots in surgery and childbirth. Despite a 19-percent increase in revenue
from 2012 to 2013, the company still faces substantial losses because of R&D
and costs associated with the product.
Piper Jaffray and Guggenheim lead the underwriting effort and expect to
price 3.6 million shares between $13 and $15.
Tokai Pharma (NASDAQ: TKAI) develops proprietary treatments for prostate
cancer. Its lead drug, Galeterone, has been tested on 250 patients in Phase
1 and Phase 2 clinical trials. Phase 3 is currently being finalized and the
company expects to get results from the FDA in the first half of 2015.
Underwriters for the offering are BMO Capital, William Blair and Stifel.
They expect to sell 5.4 million shares for $13 to $15 each.
看看明天谁发财
发信人: OKMSDN (假作真时真亦假), 信区: xiaoyaogu
标 题: 九月17号四个IPO
发信站: BBS 未名空间站 (Mon Sep 15 22:34:45 2014, 美东)
Wednesday, September 17
Home health and human services provider, Civitas Solutions (NYSE: CIVI),
serves handicapped individuals who are intellectually, behaviorally, or
physically challenged. The company focuses on providing quality programs
that are also cost effective.
As of June 30, the company had nearly 30,000 clients being served by a
workforce of 20,000. Underwriters Barclays, Merrill Lynch and UBS expect to
sell 11.7 million shares for $20 to $23 per share.
ProQR (NASDAQ: PRQR), on the other hand, is “born from the dream to beat
cystic fibrosis in one child,” according to its S-1. The company’s RNA-
based treatment is designed for use with patients suffering from cystic
fibrosis. There is also believe the treatment may address other genetic
disorders caused by single protein genetic mutation.
Underwriters Leerink Partners and Deutsche Bank expect to price 6.25 million
shares between $11 and $13 apiece.
rEVO Biologics (NASDAQ: RBIO) specializes in developing and commercializing
drugs for patients with rare, life-threatening conditions. To date, the
company has one commercial product, A Tryn, that is used to prevent blood
clots in surgery and childbirth. Despite a 19-percent increase in revenue
from 2012 to 2013, the company still faces substantial losses because of R&D
and costs associated with the product.
Piper Jaffray and Guggenheim lead the underwriting effort and expect to
price 3.6 million shares between $13 and $15.
Tokai Pharma (NASDAQ: TKAI) develops proprietary treatments for prostate
cancer. Its lead drug, Galeterone, has been tested on 250 patients in Phase
1 and Phase 2 clinical trials. Phase 3 is currently being finalized and the
company expects to get results from the FDA in the first half of 2015.
Underwriters for the offering are BMO Capital, William Blair and Stifel.
They expect to sell 5.4 million shares for $13 to $15 each.
看看明天谁发财
